CompletedPhase 4NCT01064284
Survey of Inhibitors in Plasma-Product Exposed Toddlers
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Angelo Bianchi Bonomi
- Principal Investigator
- Pier M. Mannucci, ProfessorFondazione Ca' Granda Ospedale Maggiore Policlinico Milano
- Intervention
- PLASMA DERIVED Factor VIII(drug)
- Enrollment
- 303 enrolled
- Eligibility
- 6 years · MALE
- Timeline
- 2010 – 2015
Study locations (30)
- City of Hope National Medical Center, Duarte, California, United States
- Children's Hospital Los Angeles (CHLA), Los Angeles, California, United States
- Hemophilia and Thrombosis CenterUniversity of Colorado Denver - Anschutz Aurora, Aurora, Colorado, United States
- Rush Hemophilia & Trombophilia Center - Rush University Medical Center, Chicago, Illinois, United States
- Louisiana Center for Bleeding and Clotting Disorders, Tulane University Medical Center, New Orleans, Louisiana, United States
- University of Mississippi Medical Center, Division of pediatric Hematology/Oncology, Jackson, Mississippi, United States
- Children's Mercy Hospital, Kansas City, Missouri, United States
- Hemophilia Treatment Center of Las Vegas, Las Vegas, Nevada, United States
- MeritCare Roger Maris Cancer Center, Pediatric Oncology, Fargo, North Dakota, United States
- Cook Children's Medical Center, Fort Worth, Texas, United States
- Hospital de Ninos Sor Maria Ludovica La Plata Servicio de Hematologia, La Plata, Buenos Aires, Argentina
- Fundacion de la Hemofilia, Buenos Aires, Argentina
- Landes- Frauen- und Kinderklinik Linz Abteilung für Kinder- und Jugendheilkunde, Linz, Austria
- Medizinische Universität Wien, Dept. Paediatrics, Vienna, Austria
- Centro de Pesquisa Clinica HEMORIO - Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti, Rio de Janeiro, Brazil
- +15 more locations on ClinicalTrials.gov
Collaborators
Sintesi Research Srl
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01064284 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06940830Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaSwedish Orphan Biovitrum
- RECRUITINGPHASE1NCT06703606A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.Pfizer
- RECRUITINGPHASE3NCT06833983To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AGritgen Therapeutics Co., Ltd.